Tirosina Quinase/Adaptador
Os inibidores de tirosina quinase e adaptadores são compostos que têm como alvo as tirosina quinases e suas proteínas adaptadoras associadas, que desempenham papéis fundamentais na sinalização celular, crescimento e diferenciação. Esses inibidores são ferramentas essenciais na pesquisa sobre o câncer, pois muitas tirosina quinases estão envolvidas nas vias de sinalização que impulsionam o crescimento e a metástase dos tumores. Ao inibir as tirosina quinases, esses compostos podem bloquear cascatas de sinalização críticas, oferecendo potenciais estratégias terapêuticas para vários tipos de câncer e outras doenças que envolvem sinalização celular anormal. Na CymitQuimica, oferecemos uma ampla gama de inibidores de tirosina quinase e adaptadores de alta qualidade para apoiar sua pesquisa em oncologia, biologia molecular e desenvolvimento de terapias direcionadas.
Subcategorias de "Tirosina Quinase/Adaptador"
- ALK(112 produtos)
- CSF-1R(42 produtos)
- EGFR(572 produtos)
- Receptor de Efrina(23 produtos)
- FLT(92 produtos)
- Receptor do Factor de Crescimento Fibroblasto (FGFR)(170 produtos)
- HER(5 produtos)
- Hck(3 produtos)
- IGF-1R(86 produtos)
- PDGFR(126 produtos)
- PYK2(7 produtos)
- Src(78 produtos)
- Receptor TAM(32 produtos)
- Tie-2(20 produtos)
- Receptor TrK(59 produtos)
- Tirosina Quinases(27 produtos)
- VEGFR(268 produtos)
- c-Fms(108 produtos)
- c-Kit(101 produtos)
- c-Met/HGFR(128 produtos)
- c-RET(51 produtos)
Exibir 13 mais subcategorias
Foram encontrados 1375 produtos de "Tirosina Quinase/Adaptador"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Tyrphostin A25
CAS:<p>Tyrphostin A25 (Tyrphostin AG 82) is a specific EGFR tyrosine kinase inhibitor and GPR35 agonist with an IC50 value of 0.94 μM for GPR35 and an EC50 value of 5.</p>Fórmula:C10H6N2O3Pureza:98.76%Cor e Forma:Yellow Green Powder /Off-White SolidPeso molecular:202.17PKI-166
CAS:<p>PKI-166: oral EGF-R tyrosine kinase inhibitor (IC50: 0.7 nM), halts growth & spread of many human cancers, including pancreatic.</p>Fórmula:C20H18N4OPureza:99.2%Cor e Forma:SolidPeso molecular:330.38RET-IN-3
CAS:<p>RET-IN-3 is a RETV804M kinase inhibitor with potential anticancer activity for the study of non-small cell lung cancer.</p>Fórmula:C18H21N5O2Pureza:99.52%Cor e Forma:SolidPeso molecular:339.39c-Fms-IN-13
CAS:<p>c-Fms-IN-13 (compound 14) is a potent FMS kinase inhibitor (IC50= 17 nM). c-Fms-IN-13 is an anti-inflammatory agent.</p>Fórmula:C22H26N4O2Pureza:99.93% - 99.97%Cor e Forma:SolidPeso molecular:378.47EMI1
CAS:<p>EMI1 targets mutated EGFR in drug-resistant NSCLC research.</p>Fórmula:C20H18N2O3Pureza:99.96%Cor e Forma:SolidPeso molecular:334.37EGFR-IN-9
CAS:<p>EGFR-IN-9 is a potent EGFR kinase inhibitor with IC50s of 7 nM, 28 nM for the wild type EGFR kinase and double mutant EGFR kinase (L858R/T790M).</p>Fórmula:C29H24N4O3Pureza:99.8%Cor e Forma:SolidPeso molecular:476.53CSF1R-IN-3
CAS:<p>CSF1R-IN-3 is an orally effective CSF-1R inhibitor with an IC50 value of 2.1 nM.</p>Fórmula:C30H38N8O4Pureza:97.31%Cor e Forma:SolidPeso molecular:574.67A-935142
CAS:<p>A-935142 enhances hERG (Kv 11.1) channels, slows inactivation, promotes activation, and shortens repolarization.</p>Fórmula:C18H19F3N2O2Pureza:98.97% - 99.91%Cor e Forma:SolidPeso molecular:352.35LDN-211904 oxalate
CAS:<p>LDN-211904 oxalate (LDN211904 oxalate) is a selective and efficient EphB3 inhibitor with antitumor activity, useful in neurodegenerative disease research.</p>Fórmula:C21H21ClN4O5Pureza:99.87%Cor e Forma:SolidPeso molecular:444.87AXL-IN-15
CAS:<p>AXL-IN-15 (cpd391) is a potent inhibitor of Axl, exhibiting both a dissociation constant (K i) and a half-maximal inhibitory concentration (IC50) of less than 1</p>Fórmula:C26H32F3N9O3Pureza:98%Cor e Forma:SolidPeso molecular:575.59AXL-IN-14
CAS:<p>AXL-IN-14: orally active, potent AXL inhibitor (IC50=0.8 nM); hinders Gas6/AXL migration, invasion; lowers p-AXL, p-AKT; anti-tumor.</p>Fórmula:C32H24F2N4O4Pureza:98%Cor e Forma:SolidPeso molecular:566.55VEGFR-2-IN-37
CAS:<p>VEGFR-2-IN-37 (compound 12), a VEGFR-2 inhibitor, exhibits an inhibition rate of approximately 56.9 μM at a concentration of 200 μM.</p>Fórmula:C18H16N2O2SPureza:98%Cor e Forma:SolidPeso molecular:324.4BT424
CAS:<p>BT424, a specific HCK inhibitor, modulates macrophage activation and autophagy in vitro, and mitigates inflammation and renal fibrosis in the UUO model [1].</p>Fórmula:C22H15BCl2N2O2Pureza:98%Cor e Forma:SolidPeso molecular:421.08Brepocitinib
CAS:<p>Brepocitinib (PF-06700841) is a potent dual JAK1/TYK2 inhibitor (IC50s: 17 nM/23 nM). Brepocitinib also inhibits JAK2/3 (IC50s: 77 nM/6.49 μM).</p>Fórmula:C18H21F2N7OPureza:99.82%Cor e Forma:SolidPeso molecular:389.4Axl/Mer/CSF1R-IN-2
CAS:<p>Axl/Mer/CSF1R-IN-2 (Comp 4) serves as an inhibitor for Axl, Mer, and CSF1R [1].</p>Fórmula:C24H22F3N5O5Cor e Forma:SolidPeso molecular:517.46Terevalefim
CAS:<p>Terevalefim (ANG-3777) is an hepatocyte growth factor (HGF) mimetic. Terevalefim selectively activates the c-Met receptor.</p>Fórmula:C9H8N2SPureza:99.8%Cor e Forma:SolidPeso molecular:176.24Cinsebrutinib
CAS:<p>Cinsebrutinib, a Bruton's tyrosine kinase inhibitor, holds potential for research in cancer treatment.</p>Fórmula:C22H26FN3O2Pureza:98%Cor e Forma:SolidPeso molecular:383.46BMS-599626 Hydrochloride
CAS:<p>BMS-599626 HCl (AC480 HCl) is an oral inhibitor of HER1, HER2, HER4 kinases, potentially blocking tumor growth. IC50: 22/32/190 nM.</p>Fórmula:C27H28ClFN8O3Pureza:99.98%Cor e Forma:SolidPeso molecular:567.01FGFR3-IN-7
CAS:<p>FGFR3-IN-7 is a potent, selective inhibitor of FGFR 3, demonstrating an IC50 value of less than 350 nM , and is utilized in cancer research [1].</p>Fórmula:C25H24FN9OPureza:98%Cor e Forma:SolidPeso molecular:485.52ARRY-382
CAS:<p>ARRY-382 is a highly selective oral inhibitor of CSF-1R with an IC50 of 9 nM.</p>Fórmula:C32H36N8O2Pureza:99.76%Cor e Forma:SolidPeso molecular:564.68Tyrphostin AG1433
CAS:<p>Tyrphostin AG1433 (AG1433) is an inhibitor of tyrosine kinases and also a dual inhibitor of PDGFRβ(IC50s = 5.0 μM) and VEGFR-2 (Flk-1/KDR)(IC50s = 9.3 μM).</p>Fórmula:C16H14N2O2Pureza:98.47%Cor e Forma:SolidPeso molecular:266.29Resigratinib
CAS:<p>Resigratinib (KIN-3248) is an oral, irreversible pan-FGFR family protein inhibitor, covalently binds to and inhibits all four FGFR isoforms(FGFR1/2/3/4).</p>Fórmula:C26H27F2N7O3Pureza:98.58%Cor e Forma:SolidPeso molecular:523.53BGB-102
CAS:<p>BGB-102 (JNJ-26483327) is a kinase inhibitor targeting FLT3 and YES1 and an antagonist targeting EGFR and VEGFR3.</p>Fórmula:C22H25BrN4O2Pureza:99.02%Cor e Forma:SolidPeso molecular:457.36AKB-6899
CAS:<p>AKB-6899 is an inhibitor of prolyl hydroxylase domain 3 (PHD3) and increases the soluble form of the VEGF receptor (sVEGFR-1) production from GM-CSF-treated</p>Fórmula:C14H11FN2O4Pureza:97.87%Cor e Forma:SolidPeso molecular:290.25Lifirafenib
CAS:<p>Lifirafenib (Beigene-283) is a potent inhibitor of RAF family kinases and EGFR in biochemical assays with IC50 of 23, 29 and 495 nM for the recombinant</p>Fórmula:C25H17F3N4O3Pureza:98% - 98.25%Cor e Forma:SolidPeso molecular:478.42VEGFR-2-IN-9
CAS:<p>VEGFR-2-IN-9 (KDR-in-4) is a potent KDR/VEGFR2 inhibitor (IC50: 7 nM). It can be used to study breast cancer.</p>Fórmula:C23H25N3O3Pureza:97.19%Cor e Forma:SolidPeso molecular:391.46EGFR mutant-IN-1
<p>EGFR mutant-in-1, a 5-methylpyrimidopyridone, selectively inhibits EGFRL858R/T790M/C797S mutants with an IC50 of 27.5 nM, lessening EGFRWT impact.</p>Fórmula:C34H39ClFN7O2Pureza:98%Cor e Forma:SolidPeso molecular:632.17JND3229
CAS:<p>JND3229 inhibits EGFRC797S; IC50: 5.8-30.5 nM; halts cell growth; effective in non-small cell lung cancer study.</p>Fórmula:C33H41ClN8O2Pureza:98.75%Cor e Forma:SolidPeso molecular:617.18EGFR-IN-1
CAS:<p>EGFR-IN-1: an oral, irreversible EGFR inhibitor targeting L858R/T790M mutations with high selectivity, showing potent antitumor effects.</p>Fórmula:C28H30N6O4Pureza:98%Cor e Forma:SolidPeso molecular:514.58PF-06733804
CAS:<p>PF-06733804 is a potent inhibitor of pan-Trk in cell-based assays (IC50s: 8.4 nM, 6.2 nM, and 2.2 nM for TrkA, TrkB, and TrkC) with anti-hyperalgesic effect.</p>Fórmula:C20H19F5N4O4Pureza:98%Cor e Forma:SolidPeso molecular:474.38EGFR-IN-36
CAS:<p>EGFR-IN-36 inhibits EGFR, HER2, & mutants with IC50s: 19.09 nM (EGFR WT), 120.01 nM (HER2 WT), 2.35 nM (HER2 mutant).</p>Fórmula:C26H25ClN6O2Cor e Forma:SolidPeso molecular:488.97EGFR-IN-71
CAS:<p>EGFR-IN-71 is a potent inhibitor of epidermal growth factor receptor (EGFR) (IC50= 3.7 μM). EGFR-IN-71 has research value in chordoma.</p>Fórmula:C16H9ClIN3Cor e Forma:SolidPeso molecular:405.62Pirtobrutinib
CAS:<p>Pirtobrutinib: a selective, non-covalent BTK inhibitor effective against BTK C481 mutations, causing tumor regression in lymphoma models.</p>Fórmula:C22H21F4N5O3Pureza:99.76% - 99.94%Cor e Forma:SolidPeso molecular:479.43VEGFR2-IN-3
CAS:<p>VEGFR2-IN-3 (compound 385) is a potent inhibitor of VEGFR2 [1].</p>Fórmula:C26H28ClN5O4Pureza:98%Cor e Forma:SolidPeso molecular:509.98EGFR-IN-74
<p>EGFR-IN-74 is a potent inhibitor targeting EGFR, specifically effective against the L858R/T790M mutations, exhibiting an IC50 value of 138 nM.</p>Fórmula:C32H28BrF3N6O4SCor e Forma:SolidPeso molecular:729.57TIE-2/VEGFR-2 kinase-IN-5
CAS:<p>TIE-2/VEGFR-2 kinase-IN-5 is a TIE-2 and VEGFR-2 tyrosine kinase receptor inhibitor commonly used in biomedical research related to angiogenesis.</p>Fórmula:C21H13F6N5O2Pureza:99.79%Cor e Forma:SolidPeso molecular:481.35Simotinib
CAS:<p>Simotinib (AL-6802) is an EGFR tyrosine kinase inhibitor (IC50 : 19.9 nM) with antitumour activity for the study of non-small cell lung cancer.</p>Fórmula:C25H26ClFN4O4Pureza:99.7%Cor e Forma:SolidPeso molecular:500.95EGFR-IN-29
CAS:<p>EGFR-IN-29 is a potent EGFR inhibitor.</p>Fórmula:C36H46BrN8O2PCor e Forma:SolidPeso molecular:733.68CG 428
CAS:<p>CG 428 is a potent tropomyosin receptor Kinase (TRK) Degrader (uSMITETM) with a DC50 of 0.36 nM.</p>Fórmula:C43H43FN10O6Pureza:99.83%Cor e Forma:SolidPeso molecular:814.86PAT-505
CAS:<p>PAT-505 is an autologous epidermal growth factor inhibitor.</p>Fórmula:C23H18ClF2N3O2SPureza:98.84%Cor e Forma:SolidPeso molecular:473.92Edralbrutinib
CAS:<p>Edralbrutinib (TG-1701) is a potent BTK inhibitor with anticancer activity and is used in the treatment of tumors, immune system disorders, and blood and</p>Fórmula:C26H21F2N5O3Pureza:99.41%Cor e Forma:SolidPeso molecular:489.47DYRKs-IN-2
CAS:<p>DYRKs-IN-2 has antitumor activity. DYRKs-IN-2 is a potent DYRKs inhibitor with IC50s of 30.6 nM and 12.8 nM for DYRK1B and DYRK1A, respectively.</p>Fórmula:C32H38ClN9O3Pureza:98%Cor e Forma:SolidPeso molecular:632.16c-met-IN-1
CAS:<p>c-met-IN-1 is a potent and selective c-Met inhibitor (IC50: 1.1 nM) with antitumor activity.</p>Fórmula:C35H37FN6O5Pureza:98%Cor e Forma:SolidPeso molecular:640.7HKI-357
CAS:<p>HKI-357 irreversibly inhibits EGFR/ERBB2 (IC50: 34/33 nM), blocks EGFR Y1068 autophosphorylation, and AKT/MAPK phosphorylation.</p>Fórmula:C31H29ClFN5O3Pureza:99.91%Cor e Forma:SolidPeso molecular:574.05BMX-IN-1
CAS:<p>BMX-IN-1 (BMX kinase inhibitor) is a selective inhibitor of bone marrow tyrosine kinase on chromosome X (BMX, IC50 = 8 nM) and the related Bruton’s tyrosine</p>Fórmula:C29H24N4O4SPureza:98.38%Cor e Forma:SolidPeso molecular:524.59PF-06250112
CAS:<p>PF-06250112 is an effective and highly selective BTK inhibitor (IC50: 0.5 nM.</p>Fórmula:C22H20F2N6O2Pureza:98%Cor e Forma:SolidPeso molecular:438.43PF-06459988
CAS:<p>PF-06459988 is a novel, effective, orally active, irreversible, and selective epidermal growth factor receptor (EGFR) mutant inhibitor.</p>Fórmula:C19H22ClN7O3Pureza:98%Cor e Forma:SolidPeso molecular:431.88EGFR-IN-30
CAS:<p>EGFR-IN-30 is an EGFR inhibitor (IC50: 1-10 nM, <1 nM WT/mutants) with potential in cancer research.</p>Fórmula:C28H33BrN7O2PCor e Forma:SolidPeso molecular:610.49HER2-IN-5
CAS:<p>HER2-IN-5 is an effective inhibitor of orally active HER-2.</p>Fórmula:C27H33N7O3Cor e Forma:SolidPeso molecular:503.6Nazartinib S-enantiomer
CAS:<p>Nazartinib is an EGFR inhibitor. Nazartinib S-enantiomer is the less active S-enantiomer of Nazartinib.</p>Fórmula:C26H31ClN6O2Pureza:98%Cor e Forma:SolidPeso molecular:495.02
